Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02480881 · ClinicalTrials.gov registry record · Phase 1

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

A Phase 1 study, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT02480881 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02480881, a Phase 1 study, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).

Interventions

  • DRUG BMS-663068
  • DRUG Oral Contraceptive
  • DRUG Loestrin 1.5/30

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2015-07-07
Est. Completion 2016-01-11
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT02480881

The ClinicalTrials.gov registry entry for NCT02480881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which BMS-663068 is the first listed.

NCT02480881 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02480881 about?

NCT02480881 is a clinical study titled "A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)". This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the ph...

What is the current status of trial NCT02480881?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-07-07. Estimated completion is 2016-01-11.

What interventions are being tested in trial NCT02480881?

The interventions under investigation include: BMS-663068 (DRUG), Oral Contraceptive (DRUG), Loestrin 1.5/30 (DRUG).

Who is sponsoring clinical trial NCT02480881?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.